株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

急性呼吸促迫症候群(ARDS):パイプライン分析

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 192441
出版日 ページ情報 英文 96 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.37円で換算しております。
Back to Top
急性呼吸促迫症候群(ARDS):パイプライン分析 Acute Respiratory Distress Syndrome - Pipeline Review, H2 2017
出版日: 2017年07月18日 ページ情報: 英文 96 Pages
概要

急性呼吸促迫症候群(ARDS)は、肺の中の小さな弾性の空気嚢(肺胞)に体液が溜まると生じます。よく見られる根本的な原因として、敗血症、有害物質の吸入、重症肺炎、頭部や胸部の外傷などが挙げられます。兆候と症状は、重度の息切れ、呼吸困難、異常に速い呼吸、低血圧、精神錯乱、極度の疲労などが見られます。

当レポートでは、急性呼吸促迫症候群(ARDS)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

急性呼吸促迫症候群(ARDS)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Altor BioScience Corporation
  • Athersys, Inc.
  • Faron Pharmaceuticals Oy
  • FirstString Research, Inc.
  • GlaxoSmithKline Plc
  • Histocell S.L.
  • Phylogica Limited
  • Serendex Pharmaceuticals A/S
  • Silence Therapeutics Plc
  • Therabron Therapeutics, Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ALT-836
  • BIO-10901
  • CG-367
  • Cyndacel-M
  • GSK-2586881
  • GSK-2862277
  • インターフェロンβ-1a
  • molgramostim
  • 感染症・呼吸器疾患用 uPA阻害モノクローナル抗体
  • 肺動脈高血圧症用エンドセリン-1阻害オリゴヌクレオチド
  • PF-05285401
  • PYC-35
  • PYC-36
  • PYC-38
  • PYC-98
  • 急性肺損傷・急性呼吸促迫症候群用組換タンパク質
  • S-1229
  • SAN-101
  • 免疫学・呼吸器/筋骨格障害用MMP・サイトカイン阻害小分子
  • 炎症性肺疾患用幹細胞療法
  • 急性呼吸促迫症候群用間質細胞療法
  • 急性肺損傷・急性呼吸促迫症候群用合成ペプチド

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9571IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2017, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 2, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acute Respiratory Distress Syndrome - Overview
    • Acute Respiratory Distress Syndrome - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Acute Respiratory Distress Syndrome - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
    • Athersys Inc
    • Commence Bio Inc
    • Cynata Therapeutics Ltd
    • Faron Pharmaceuticals Oy
    • GlaxoSmithKline Plc
    • Hydra Biosciences Inc
    • Implicit Bioscience Ltd
    • Navigen Inc
    • ProMetic Life Sciences Inc
    • Savara Inc
    • Silence Therapeutics Plc
    • SolAeroMed Inc
    • Windtree Therapeutics Inc
  • Acute Respiratory Distress Syndrome - Drug Profiles
    • Aerosurf - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-10901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMB-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2586881 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2862277 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HC-067047 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IC-14 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon beta-1a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lucinactant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • molgramostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit uPA for Acute Lung Injury,Acute Respiratory Distress Syndrome and Sepsis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAV-5093 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide to Inhibit Endothelin-1 for Lung Cancer, Pulmonary Arterial Hypertension and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-05285401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plasminogen (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-1229 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAN-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • simvastatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TCP-25 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Acute Respiratory Distress Syndrome - Dormant Projects
  • Acute Respiratory Distress Syndrome - Discontinued Products
  • Acute Respiratory Distress Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • May 08, 2017: Faron Pharmaceuticals: Update on INTEREST Phase III Study for Traumakine in ARDS from IDMC
      • Oct 31, 2016: New Patent Application Accepted by Finnish Patent Office Protect the intravenous use of interferon-beta in a novel formulation
      • Oct 24, 2016: First Traumakine Phase III patient in Japan recruited for the treatment of acute respiratory distress syndrome and Update on Pan-European Phase III Traumakine trial
      • Sep 03, 2016: Queen's University Developing New Drug against Leading Causes of Death in the UK - Sepsis and Ards
      • May 25, 2016: First patient dosed in Savaras pivotal trial for PAP
      • Mar 01, 2016: Faron files patent application to further strengthen protection for its novel Traumakine (FP-1201-lyo) formulation
      • Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS
      • Dec 29, 2015: First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome
      • Oct 19, 2015: Serendex to initiate pivotal phase II/III clinical trial for PAP
      • Aug 09, 2015: Serendex to initiate first phase II clinical trial
      • Jun 10, 2015: Recruitment of ARDS patients for Serendex phase II clinical trial to commence in November
      • May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced
      • May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical's inhalable biological drug for treatment of severe pulmonary diseases
      • May 10, 2015: Positive topline data from Serendex phase I clinical trial
      • Feb 27, 2015: Serendex submits phase I application
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Athersys Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Commence Bio Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Cynata Therapeutics Ltd, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Implicit Bioscience Ltd, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Navigen Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by ProMetic Life Sciences Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Savara Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Silence Therapeutics Plc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by SolAeroMed Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Pipeline by Windtree Therapeutics Inc, H2 2017
  • Acute Respiratory Distress Syndrome - Dormant Projects, H2 2017
  • Acute Respiratory Distress Syndrome - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Acute Respiratory Distress Syndrome - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top